

## Notice of Change in Significant Shareholder

April 10, 2015, Osaka, Japan-- Santen Pharmaceutical Co., Ltd. ("Santen") announced a change in significant shareholder as of April 2, 2015.

### 1. Details of Change

On April 9, 2015, a shareholder's report related to the shareholder, Massachusetts Financial Services Company, was filed with the Kanto Local Finance Bureau indicating a change in significant shareholder as follows.

### 2. Description of Shareholder

- |                           |  |
|---------------------------|--|
| ① Name of shareholder     | Massachusetts Financial Services Company             |
| ② Address                 | 111 Huntington Avenue, Boston, Massachusetts, U.S.A. |
| ③ Representative          | Robert J. Manning, Chairman and CEO                  |
| ④ Description of business | Asset Management                                     |

### 3. Number and Percentage of Voting Rights Owned by the Shareholder

	Shareholder voting rights (total shares)	Percentage of voting rights held	Shareholder ranking
Before (as of July 28, 2014)	435,899 units (43,589,960 shares)	10.56%	1 <sup>st</sup>
After (as of April 9, 2015)	396,281 units (39,628,160 shares)	9.60%	1 <sup>st</sup>

Note 1 5-for-1 stock split was conducted as the effective date, April 1, 2015. For ease of comparability, calculations of ownership levels described assume the stock split had been implemented as of July 28, 2014. Note 2 lists the assumptions used for shares and voting rights outstanding.

Note 2 Shares outstanding were 413,059,515 as of September 30, 2014. The above calculations are based on total voting rights of 4,126,795 units and deduct non-voting shares of 380,015.

Note 3 Above numbers are based on the significant shareholdings report filed by said shareholders. Santen has not confirmed the actual number of shares held as stated in the shareholder registry. As a result, shareholder rankings above reflect the holdings of other shareholders as of the September 30, 2014 shareholder registry.

**About Santen**

As a specialty company dedicated to the ophthalmic and anti-rheumatic fields, Santen carries out the research, development, sales, and marketing of pharmaceuticals. The company has its bases in about 20 countries and delivers products in more than 70 countries. In Japan, Santen holds the No. 1 share in the prescription ophthalmic pharmaceutical market. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs.

**Contact**

Takashi Hibi

General Manager

Corporate Communication Group

Santen Pharmaceutical Co., Ltd.

E-mail: [ir@santen.co.jp](mailto:ir@santen.co.jp)

Tel: +81-6-4802-9360